• LAST PRICE
    0.3758
  • TODAY'S CHANGE (%)
    Trending Down-0.0083 (-2.1609%)
  • Bid / Lots
    0.2925/ 10
  • Ask / Lots
    0.3700/ 19
  • Open / Previous Close
    0.3700 / 0.3841
  • Day Range
    Low 0.3601
    High 0.3850
  • 52 Week Range
    Low 0.3601
    High 5.0800
  • Volume
    138,218
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.3841
TimeVolumeADIL
09:32 ET105970.365
09:36 ET4000.365
09:38 ET35000.38
09:45 ET4100.3699
09:48 ET8000.3799
09:50 ET37600.379799
10:01 ET2000.362
10:12 ET32000.37
10:17 ET10000.362301
10:19 ET30000.378
10:21 ET58000.37
10:24 ET11000.3602
10:32 ET121000.37
10:44 ET4500.384799
10:46 ET1000.38
10:53 ET1000.3798
10:55 ET11000.3799
11:18 ET2500.37989
11:24 ET1730.3751
11:49 ET26490.3799
11:51 ET572880.3649
11:54 ET1000.379785
11:58 ET2000.3652
12:09 ET29000.370001
12:18 ET1000.3799
12:27 ET12000.3798
12:45 ET63000.3798
01:39 ET2310.381976
01:46 ET27000.3773
01:51 ET1000.384
02:40 ET1000.3754
02:47 ET9260.3779
02:49 ET7000.38
02:51 ET10000.378001
03:00 ET6000.38
03:03 ET40000.38
03:05 ET40000.3814
03:09 ET2000.375499
03:20 ET2000.3755
03:21 ET10000.3772
03:38 ET11460.3798
03:54 ET1810.3758
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesADIL
Adial Pharmaceuticals Inc
10.1M
-0.5x
---
United StatesBLPH
Bellerophon Therapeutics Inc
10.0M
-0.5x
---
United StatesADXN
Addex Therapeutics Ltd
9.8M
0.0x
---
United StatesQSAM
Qsam Biosciences Inc
9.7M
-0.8x
---
United StatesBRTX
BioRestorative Therapies Inc
9.7M
-0.2x
---
United StatesPKTX
ProtoKinetix Inc
10.7M
-3.7x
---
As of 2022-09-25

Company Information

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of medications for the treatment of addictions and related disorders. Its lead investigational drug product is AD04. AD04 is being developed for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. AD04 is being designed to be used for the treatment of other addictive disorders, such as opioid use disorder, obesity, smoking, and other drug addictions.

Contact Information

Headquarters
1180 SEMINOLE TRAIL, SUITE 495CHARLOTTESVILLE, VA, United States 22901
Phone
434-422-9800
Fax
302-655-5049

Executives

Independent Chairman of the Board
Kevin Schuyler
President, Chief Executive Officer, Director
Cary Claiborne
Chief Financial Officer, Treasurer, Company Secretary
Joseph Truluck
Chief Executive Officer - Purnovate, Director
William Stilley
Chief Medical Officer
Bankole Johnson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.1M
Revenue (TTM)
$0.00
Shares Outstanding
26.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.58
EPS
$-0.78
Book Value
$0.17
P/E Ratio
-0.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.